EyeGate Pharma Strengthens Scientific Advisory Board with Appointments of Daniel S. Durrie, M.D. and Randall J. Olson, M.D.
WALTHAM, Mass., March 13, 2017 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage specialty pharmaceutical company that focuses on developing and commercializing products for treating diseases and disorders of the eye, today announced the appointment of two leading ophthalmology experts, Daniel S. Durrie, M.D. and Randall J. Olson, M.D., to its Scientific Advisory Board (the “SAB”). Drs. Durrie and Olson will work together with the other members of EyeGate’s SAB to provide the Company strategic guidance and support the continued development of its ophthalmic platforms, EGP-437 and EyeGate OBG.
“We are proud to welcome Daniel and Randall to the EyeGate’s SAB. They are both highly distinguished ophthalmologists with a deep understanding of our target markets,” said Stephen From, Chief Executive Officer of EyeGate. “We look forward to leveraging their extensive scientific and clinical expertise as we continue to advance our therapeutic candidates and apply our highly innovative ophthalmic platforms to develop new treatment options for patients in need.”
Daniel S. Durrie, M.D. has more than 30 years of experience in refractive and corneal surgery and is a pioneer in refractive surgery technology and procedures. He is a board-certified ophthalmologist and currently serves as a Clinical Professor and Director of Refractive Surgery Services at the University of Kansas Medical Center. Dr. Durrie was named one of the 50 “Most Influential Ophthalmologists in the World” by the Cataract and Refractive Surgery Magazine. His research focuses on advancements in vision correction technology. He has participated in over 150 FDA clinical studies and has authored over 150 peer-reviewed scientific journal articles. He received his medical degree and completed his ophthalmology residency at the University of Nebraska, graduating with distinction. He completed a Corneal Fellowship with Filkins Eye Institute in Omaha, Nebraska.
Randall J. Olson, M.D. is a board-certified ophthalmologist with more than 30 years of experience. Currently, he serves as Chief Executive Officer of the John A. Moran Eye Center and Presidential Endowed Professor at University of Utah School of Medicine. Dr. Olson specializes in research dealing with cataract surgery, intra-ocular lens complications, teleophthalmology and corneal transplantation techniques. He is the author of more than 300 publications, and was selected as one of the 15 best cataract surgeons in the United States by Ophthalmology Times. He received his medical degree from University of Utah School of Medicine and completed his residency in ophthalmology at the University of California - Los Angeles.
About EyeGate:
EyeGate is a clinical-stage specialty pharmaceutical company that is focused on developing and commercializing products for treating diseases and disorders of the eye. EGP-437, EyeGate’s first product in clinical trials, incorporates a reformulated topically active corticosteroid, Dexamethasone Phosphate, that is delivered into the ocular tissues through EyeGate’s proprietary innovative drug delivery system, the EyeGate II Delivery System. In addition, EyeGate is developing, through its wholly-owned Jade subsidiary, products using cross-linked thiolated carboxymethyl hyaluronic acid (“CMHA-S”), a modified form of the natural polymer hyaluronic acid (HA), which possesses unique physical and chemical properties such as hydration and healing properties. The ability of CMHA-S to adhere longer to the ocular surface, resist degradation and protect the ocular surface makes it well-suited for treating various ocular surface injuries. For more information, please visit www.EyeGatePharma.com.
Forward-looking Statements
Some of the statements in this press release are “forward-looking” and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These “forward-looking” statements include statements relating to, among other things, the commercialization efforts and other regulatory or marketing approval efforts pertaining to EyeGate’s products, including EyeGate’s EGP-437 combination product and those of Jade, a wholly owned subsidiary of EyeGate, as well as the success thereof, with such approvals or success may not be obtained or achieved on a timely basis or at all. These statements involve risks and uncertainties that may cause results to differ materially from the statements set forth in this press release, including, among other things, certain risk factors described under the heading “Risk Factors” contained in EyeGate’s Annual Report on Form 10-K filed with the SEC on February 23, 2017 or described in EyeGate’s other public filings. EyeGate’s results may also be affected by factors of which it is not currently aware. The forward-looking statements in this press release speak only as of the date of this press release. EyeGate expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions or circumstances on which any such statement is based.
Contact: Lee Roth / Janhavi Mohite The Ruth Group for EyeGate Pharmaceuticals 646-536-7012 / 7026 lroth@theruthgroup.com / jmohite@theruthgroup.com
Released March 13, 2017